Advertisement

Kosten der genetischen Beratung und der molekulargenetischen Diagnostik bei BRCA-Mutationen

  • Alexander Haverkamp
  • Ansgar Gerhardus
  • Christian Krauth
Chapter

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bundesministerium der Finanzen (2004a): AfA-Tabelle für die allgemein verwendbaren Anlagegüter. Quelle: http://www.bundesfinanzministerium.de/dokumente/ix-..15472/Artikel.htm, letzter Zufgriff 27.08.2004Google Scholar
  2. Bundesministerium der Finanzen (2004b): Sachkostenpauschale eines Arbeitsplatzes in der Bundesverwaltung. Quelle: http://www.bundesfinanzministerium.de/dokumente/ix-..1844/Artikel.htm, letzter Zufgriff 27.08.2004Google Scholar
  3. Cromwell D.M (1998): Cost Analysis of Alternative Approaches to Colorectal Screening in Familial Adenomatous Polyposis. Gastroenterology 114: 893–901CrossRefPubMedGoogle Scholar
  4. Europäisches Patentamt (2004): „Myriad/breast cancer“ patent revoked after public hearing. Pressemitteilung vom 18.05.2004. Quelle: http://www.european-patent-office.org/news/pressrel/2004_05_18_e.htm, letzter Zugriff 24.08.2004Google Scholar
  5. German consortium of hereditary breast and ovarian cancer (2002). Comprehensive Analysis of 989 Patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the german population. Int J Cancer 97: 472–480Google Scholar
  6. Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI (1999) Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol. 17:494–500PubMedGoogle Scholar
  7. Griffith GL, Edwards RT, Gray J (2004) Cancer genetics services: a systematic review of the economic evidence and issues. Br J Cancer. 90:1697–703CrossRefPubMedGoogle Scholar
  8. Institut für Arbeitsmarkt-und Berufsforschung (IAB) (2004) Kurzbericht Nr. 5 Quelle: http://www.iab.de/asp/internet/dbdokShow.asp?pkyDoku=k040315n01, letzter Zufgriff 27.08. 2004Google Scholar
  9. Lawrence WF, Peshkin BN, Liang W, Isaacs C, Lerman C, Mandelblatt JS (2001) Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol Biomarkers Prev. 10:475–81PubMedGoogle Scholar
  10. National Institute for Clinical Excellence, London. (2004) NICE Clinical Guideline 14: Familial breast cancer. The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care.Google Scholar
  11. Sevilla C (2003) Evaluation economique des innovations biomedicales: l’exemple de la diffusion des tests genetiques en oncologie. Diss. (Marseille)Google Scholar
  12. Sevilla C, Julian-Reynier C, Eisinger F, Stoppa-Lyonnet D, Bressac-de Paillerets B, Sobol H, Moatti JP (2003) Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing. Int J Technol Assess Health Care. 19: 287–300PubMedGoogle Scholar
  13. Tengs TO, Berry DA (2000) The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Dis. Manag. Clin. Outcomes. 1: 15–24Google Scholar
  14. Vasen HF, van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G, Nagengast FM, Menko FH, Meera Khan P (1998) A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer. 82:1632–7CrossRefPubMedGoogle Scholar
  15. Wallace AJ, Wu CL, Elles RG (1999) Meta-PCR: A novel method for creating chimeric DNA molecules and increasing the productivity of mutation scanning techniques. GenetTest. 3: 173–83Google Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2005

Authors and Affiliations

  • Alexander Haverkamp
    • 1
  • Ansgar Gerhardus
    • 1
    • 2
  • Christian Krauth
    • 1
  1. 1.Abteilung Epidemiologie, Sozialmedizin und GesundheitssystemforschungMedizinische Hochschule HannoverHannover
  2. 2.Institut für Gesundheits- und MedizinrechtUniversität Bremen, FB 6Bremen

Personalised recommendations